MEDIFIRST SOLUTIONS APPOINTS BILL WHITE TO ITS ADVISORY BOARD
November 22 2016 - 10:29AM
InvestorsHub NewsWire
Freehold, NJ – November 22, 2016 -- InvestorsHub
Newswire – MEDIFIRST SOLUTIONS, INC. (OTCQB:
MFST) (the “Company” or “Medifirst”) A provider of innovative
laser technology with its FDA 510(k) cleared Infrared Time Machine
TTML-8102000 Laser Thermal Therapeutic Device is pleased to
announce the appointment of Bill White to its Advisory Board. Mr.
White will serve as a senior advisor to CEO Bruce J.
Schoengood.
Bill White is Chief Financial Officer, Treasurer and Board
Secretary of Intellicheck Mobilisa, a leading software technology
company providing wireless technology and identity systems for
various applications including mobile and handheld, access control
and security systems for the commercial, government and military
markets. Bill White has more than 28 years of experience in
financial management, operations and business development. In
addition to his experience as an officer of Intellicheck Mobilisa,
he served 11 years as the Chief Financial Officer, Secretary and
Treasurer of FocusMicro, Inc. (FM). As co-founder of FM, Mr. White
played an integral role in growing the business from the company's
inception to over $36 Million in annual revenue in a five year
period. Mr. White has broad domestic and international
experience including managing rapid and significant growth,
import/export, implementing tough cost management initiatives,
exploiting new growth opportunities, merger and acquisitions,
strategic planning, resource allocation, tax compliance and
organization development. Prior to co-founding FM, he served 15
years in various financial leadership positions in the government
sector.
Mr. White stated, “I'm very excited and pleased to join the
Medifirst Solutions Advisory Board. The laser sector within
the healthcare industry is booming and The Time Machine Lasers
present a unique product with explosive growth potential. I look
forward to assisting the company in monetizing its incredible
technology.” Stated CEO Bruce J. Schoengood, “Bill is a key
addition to our team. He brings decades of management experience
that will be invaluable to Medifirst as it now enters its sales,
marketing and distribution phase. We are honored and excited
to have him join our Board as a senior advisor.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket
Notification 510(k) submission for “The Time Machine” Series Laser,
received clearance from the U.S. Food and Drug Administration
(“FDA”) to market its infrared Time Machine TTML-8102000 Laser
Thermal Therapeutic Device. The Time Machine Series Lasers Model
TTML-8102000 - 810/830nm is intended for use in temporary relief of
minor muscle and joint pain, stiffness, minor arthritis pain,
muscle spasm, temporary increase in local blood circulation and
temporary relaxation of muscles by means of topical elevated tissue
temperature from infrared spectral emissions. Due to the
decrease of inflammation, patients have seen immediate aesthetic
improvements as well, such as in scar and incision healing. The
hand-held laser device, with pin-point accuracy, often gives
patients immediate results with no redness, swelling or down-time.
This unique laser device offers medical professionals an affordable
and effective tool to enhance their treatment protocols for their
patients and provide new revenue streams for their practice. The
laser division will be operated out of Medifirst's wholly owned
subsidiary, Medical Lasers Manufacturer. Visit
www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's
expectations with regard to the future impact on the company's
results from new products in development are forward-looking
statements, and may involve risks and uncertainties, some of which
are beyond our control. Such risks and uncertainties are
described in greater detail in our filings with the U.S. Securities
and Exchange Commission. Since the information in this press
release may contain statements that involve risk and uncertainties
and are subject to change at any time, the company's actual results
may differ materially from expected results. We make no
commitment to disclose any subsequent revisions to forward-looking
statements. This release does not constitute an offer to sell or a
solicitation of offers to buy any securities of any entity.